HealthCare Institute of New Jersey (HINJ) President and CEO Chrissy Buteas has voiced support for the contributions of life sciences companies to healthcare. This statement comes after the Trump administration recommended earlier in the week that women should limit their use of Tylenol during pregnancy unless it is medically necessary.
Buteas stated, “From rigorous R&D and clinical trials to comprehensive approval and regulatory processes, life sciences companies have long partnered with safety and efficacy agencies in the U.S. and globally to ensure that patient safety remains the cornerstone of advancing human health.”
The recent federal recommendation regarding Tylenol use during pregnancy has prompted responses from various stakeholders in the healthcare sector, highlighting ongoing discussions about medication safety for expectant mothers.
